Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
2024-520137-74-00Phase 2Authorised
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 6
01
Overview
Phase 2, randomised trial of vosoritide in Idiopathic Short Stature (ISS) (2 arms), sponsored by BioMarin Pharmaceutical. Primary endpoints: Change from baseline in annualized growth velocity at 6 months (dose-finding phase), Change from baseline in height at 4 years (long-term phase) and 1 more. Planned start Jun 2025; status: authorised.
02
Drugs
vosoritide
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on 2024-520137-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520137-74-00.